Condition
Nalbuphine as an Adjuvant to L. A in Peribulbar Block for Cataract Surgery
Total Trials
1
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Lidocaine Bupivacaine Hyaluronidase Saline
Research Leaders
7 sponsors active, led by Mohamed, Ahmed A., M.D.
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Lidocaine Bupivacaine Hyaluronidase Saline1
- Nalbuphine1
- Lidocaine Bupivacaine Hyaluronidase1
Active Sponsors
- Mohamed, Ahmed A., M.D.1
- Cairo University1
- Nadia Yossif Helmy1
- Atef Kamel Salama1
- Mostafa Abdalwahab Elberry1